Dr. Rizzo discusses research that he and his co-authors presented at the 2025 AAD Annual Meeting, which validated the performance of the 31-gene expression profile (GEP) test in a large, unselected cohort by demonstrating melanoma-specific survival stratification and survival benefit in 31-GEP-tested patients in an updated analysis of almost 10,000 clinically tested patients included in SEER registry data. View the full poster here.
